Barclays analyst Matt Miksic lowered the firm’s price target on Insulet to $213 from $214 and keeps an Equal Weight rating on the shares. The company’s Q4 U.S. Omnipod sales were up 30% after adjusting for accelerated orders and inventory restocking, the analyst tells investors in a research note.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on PODD:
- Insulet sees FY24 revenue growth 12%-17%, consensus $1.98B
- Insulet sees Q1 revenue growth 17%-20%, consensus $442.48M
- Insulet reports Q4 adjusted EPS $1.40, consensus 66c
- PODD Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Insulet gets CE Mark approval of Omnipod 5 integration with FreeStyle Libre 2